|
|
Blood, Vol. 111, Issue 11, 5371-5379, June 1, 2008
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study
Blood Langer et al.
111: 5371
Supplemental materials for: Langer et al
Files in this Data Supplement:
- Document 1. Supplemental materials and methods (PDF, 14.7 KB)
- Document 2. Cancer and Leukemia Group B institutions, principal investigators, and cytogeneticists who participated in this study (PDF, 16.9 KB)
- Table S1. Probe sets in the BAALC signature that are overexpressed in the high BAALC group (XLS, 97.5 KB)
- Table S2. Probe sets in the BAALC signature that are underexpressed in the high BAALC group (XLS, 78.5 KB)
- Figure S1. Distribution of individual BAALC expression levels at diagnosis by treatment protocol (JPG, 41.5 KB)
-
Expression values for patients enrolled on protocol 9621 are represented by blue diamonds and for patients enrolled on protocol 19808 by green circles.
- Figure S2. Disease-free (A) and overall survival (B) of cytogenetically normal AML patients according to BAALC expression levels grouped by quartiles (JPG, 33 KB)
-
P-values were calculated using the log-rank test for trend.
- Figure S3. Individual BAALC expression levels and corresponding expression levels of miR-148a in nine cytogenetically normal AML patients (1-9) (JPG, 30.9 KB)
-
- Figure S4. Dot plots representing individual levels of miR-148a expression (JPG, 23.6 KB)
-
Normal, miR-148a values of four healthy volunteers; AML, miR-148a values of nine cytogenetically normal AML patients; KG1a, miR-148a expression value in the BAALC expressing cell line KG1a. Short horizontal lines represent median miR-148a values for the normal and AML groups.
|
|
